Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
Teva Pharmaceuticals granted final approval for Ribavirin capsules

Teva Pharmaceuticals granted final approval for Ribavirin capsules

Lassa Fever, not seen in US for 15 years re-emerges

Lassa Fever, not seen in US for 15 years re-emerges

Neck surgeons brush up on West Nile virus

Neck surgeons brush up on West Nile virus

Widely used antimalarial drug exhibits antiviral activity against the SARS

Widely used antimalarial drug exhibits antiviral activity against the SARS

Peginterferon and Ribavirin combination promising for those with HIV and HCV

Peginterferon and Ribavirin combination promising for those with HIV and HCV

Study shows safe, effective therapy for previously untreated patients with HIV & hepatitis C

Study shows safe, effective therapy for previously untreated patients with HIV & hepatitis C

New drug combination more effective than the previous generation of hepatitis C/HIV therapy

New drug combination more effective than the previous generation of hepatitis C/HIV therapy

Treatment of chronic hepatitis C with interferon can be ineffective due to relapse

Treatment of chronic hepatitis C with interferon can be ineffective due to relapse

Treatment helps 26% of black Americans with chronic hepatitis C

Treatment helps 26% of black Americans with chronic hepatitis C

New study challenges current thinking about varied response to hepatitis C treatment in different racial groups

New study challenges current thinking about varied response to hepatitis C treatment in different racial groups

Human Genome Sciences has begun dosing patients with chronic hep C drug

Human Genome Sciences has begun dosing patients with chronic hep C drug

Largest study comparing leading hepatitis C treatments

Largest study comparing leading hepatitis C treatments

Severe Acute Respiratory Syndrome (SARS) overview

Severe Acute Respiratory Syndrome (SARS) overview

Schering-Plough submits Japanese application for hepatitis C drug

Schering-Plough submits Japanese application for hepatitis C drug

Oral treatment of chronic hepatitis C

Oral treatment of chronic hepatitis C

Generic ribavirin product launched in the United States

Generic ribavirin product launched in the United States

Haemophilia Society President presents Hepatitis C (HCV) Facts to UK Government

Haemophilia Society President presents Hepatitis C (HCV) Facts to UK Government